Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Plasma samples.
- Who it may be relevant to
- Registry conditions: Squamous Cell Carcinoma of the Head and Neck. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck
Overview
The investigators will collect plasma samples at baseline, during treatment, and at progression.
Detailed description
In this study, the investigators will collect plasma samples at baseline, during treatment, and at progression. This plasma bank will be used to study the potential value of some biomarkers to predict treatment activity or resistance to cetuximab or other targeted agents
Interventions
- Other Plasma samples
Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
Primary outcome measures
- Prospective storage of plasma samples of patients treated with cetuximab or other targeted agents [Time frame: one year after the collection]
Eligibility criteria
Inclusion criteria
- patients treated with radiation therapy and cetuximab according to Bonner et al
- patients treated with cetuximab in combination with chemotherapy according to Vermorken et al.
- patients treated with a molecular targeted agent as a part of a clinical study
Exclusion criteria
- patients with another type of head and neck cancer
- patients non treated with targeted therapies
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Belgium · 5 centers
- Clinique Saint-Pierre — Ottignies
- Grand Hôpital de Charleroi — Charleroi
- Centre Hospitalier Jolimont-Lobbes-Nivelles-Tubize — Haine-Saint-Paul
- CHU Liège — Liège
- Clinique et Maternité Sainte-Elisabeth — Namur
Identifiers
NCT: NCT02139020 · UCL-ONCO 2013-01